Review decision - November 2020

Decision that the existing guidance remains unchanged

We would like to update you on the decision made regarding the review of the existing guidance on TA448; Etelcalcetide for treating secondary hyperparathyroidism.

We did not identify any new clinical evidence that would change the existing recommendations in TA448. There is no new evidence to address the uncertainty associated with extrapolating short-term surrogate outcomes to long-term outcomes such as mortality.

NICE’s Guidance Executive has decided to proceed with this proposal without consultation.

Consequently TA448 will remain unchanged unless NICE becomes aware of substantive information which would make it reconsider.

Review decision paper

Stakeholder list

This page was last updated: